Dermatomyositis with superimposed COVID-19 myositis

Abstract

study was to evaluate factors that interfere in the surgical response and the degree of postoperative satisfaction. MethodsThis research was approved by the Ethics Research Committee (48320815.1.0000.5553). We evaluated 74 patients who underwent surgery for CTS. Factors such as sex, age, body mass index, occupation, comorbidities, lifestyle, and surgical response were studied. If the symptoms persist, the patient's satisfaction degree was assessed, categorized as dissatisfied and unresponsive to treatment. ResultsSixty-eight were women. Mean age of the patients was 48 years. Twenty-three patients were obese. Thirty-one were homemakers or manual workers. Of the 67 patients evaluated, 48 (71.64%) were dissatisfied and categorized as not responding to surgical treatment. Linear regression analysis identified that alcoholism, at the time of surgery, was a significant factor, leading to 3.5 times more complications than in the non-alcoholic group (p = 0.05). In the smoking group, the complication rate was 1.2 times lower (p = 0.1). Other variables studied did not interfere with the surgical response. ConclusionsMost patients were categorized as dissatisfied and unresponsive to surgical treatment. The alcoholism was the only factor identified as relevant to the increase in complications. Paradoxically, smoking was configured as a protective factor, which may reflect a bias in the sample selection.

Dermatomyositis Flare After a COVID-19 Infection Successfully Treated with Rituximab: A Case Report and Literature Review

“…20,21 Most of the reported cases had DM either during, shortly after, or up to 2 months following COVID-19. 5,10,12,[15][16][17][18][19][20][21][22] The case series reported by Gokhale et al 5 were diagnosed with DM before COVID-19 infection, similar to the case we present in this review, and their disease was exacerbated shortly before or during the COVID-19 infection. 5 The weakness in the 13 reported cases ranged from severe weakness MRC grade 1/5 to mild weakness MRC grade 4/5.…”

“…In the literature, several cases have been reported to occur in the context of COVID-19 infection or vaccination. 5,10,12,[15][16][17][18][19][20][21][22] Table 1 summarizes the clinical characteristics, laboratory and investigational findings, treatment received, outcome, and temporal relation of DM to the COVID-19 infection. Table 2 outlines the same in relation to DM flare post-COVID vaccination.…”

“…5 The weakness in the 13 reported cases ranged from severe weakness MRC grade 1/5 to mild weakness MRC grade 4/5. 5,10,12,[15][16][17][18][19][20][21][22] Systemic manifestations included ILD, 19,22 polyarthritis, 16 and cardiomyopathy. 16,21,22 In the vast majority of reported cases, pulse intravenous methylprednisolone and/or IVIG were used to treat DM exacerbation.…”